fluorouracil + epirubicin + cyclophosphamide + taxane

This combination refers to a chemotherapy regimen commonly used in the treatment of breast cancer. It typically involves sequential administration of fluorouracil (5-FU), epirubicin, and cyclophosphamide (collectively known as FEC or CEF), followed by a taxane such as paclitaxel or docetaxel. The regimen is designed to maximize tumor cell kill through different mechanisms of action and reduce the risk of resistance. It is most often used in the adjuvant or neoadjuvant setting for early-stage or locally advanced breast cancer[4][2][5]. The mechanism involves DNA damage induction (fluorouracil and cyclophosphamide), topoisomerase II inhibition (epirubicin), and microtubule stabilization leading to mitotic arrest (taxanes).

Other names

FEC followed by paclitaxelCEF followed by paclitaxelsequential anthracycline/taxane regimen